Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 4 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11981912

    Adeno associated virus vectors for the treatment of hunter disease

    Takeda Pharmaceutical Company Limited · Granted May 14, 2024 · Expires May 9, 2044

    granted
  2. US 11976293

    Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies

    The Regents of the University of California · Granted May 7, 2024 · Expires May 2, 2044

    granted
  3. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  4. US 11965166

    Complement factor B (CFB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  5. US 11964000

    Cancer treatment methods using nanofiber stabilized growth factors

    Northwestern University · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  6. US 11965190

    Vectors, genetically modified bacteria, and methods of making and using

    Regents of the University of Minnesota · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  7. US 11946065

    Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB

    The Board of Regents of the University of Texas System · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  8. US 11926830

    Modulators of Complement Factor B

    Ionis Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  9. US 11925675

    Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  10. US 11918660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  11. US 11890354

    Activatable antibodies that bind epidermal growth factor receptor and methods thereof

    CytomX Therapeutics, Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  12. US 11891436

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)

    Julius-Maximilians-Universitat Wurzburg · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  13. US 11879017

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  14. US 11859020

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  15. US 11851440

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    DENALI THERAPEUTICS INC. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  16. US 11845959

    Identification of factor that promotes human HSC self-renewal

    The Regents of the University of California · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  17. US 11827713

    Chimeric antibody immune effector cell engagers and methods of use thereof

    Nanjing Legend Biotech Co., Ltd · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  18. US 11826464

    Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  19. US 11819517

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  20. US 11821008

    Liver targeting adeno-associated viral vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  21. US 11814641

    Retroviral and lentiviral vectors

    AUTOLUS LIMITED · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  22. US 11813316

    Lentiviral vector for treating hemoglobin disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  23. US 11802292

    Modified orthopoxvirus vectors

    TURNSTONE BIOLOGICS CORP. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted
  24. US 11779660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted